TAB014 Compared to Lucentis® in Patients With Neovascular Age-related Macular Degeneration
Status:
Recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, multi-center, double blind, Lucentis controlled non-inferiority
study in neovascular age-related macular degeneration patients. The objective of this study
is to compare the efficacy and safety of TAB014 and ranibizumab (Lucentis).